Clinical Trial Update: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on Phase 1/2 evaluation of HX009, a recombinant bifunctional antibody targeting CD47 and PD-1, in patients with relapsed or r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• HX009

Snippet

Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. | Conditions: Relapsed/Refractory Lymphoma | Phase 1, Phase 2 | Status: COMPLETED